Study of SPT-300 for major depression with or without anxiety
Part of Mental health clinical trials.
This trial tests an experimental oral medication, SPT-300, for people with major depressive disorder, even if they also have mild anxiety. The goal is to see if it helps improve mood safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are between 18 and 65 years old.
- Have been diagnosed with major depression, with or without an anxiety disorder.
- Your current depressive episode started at least 4 weeks ago but no more than 18 months ago.
- Have a body mass index (BMI) between 18 and 40.
- Agree not to use recreational drugs during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who finished the earlier BUOY-1 study of SPT-300 and want to continue treatment. It tests the long-term safety and tolerability of SPT-300 for major depressive disorder, with or without anxious distress.
This trial tests an investigational medication for adults with major depressive disorder who are currently taking an antidepressant but still have symptoms. It aims to see if adding this new drug can improve mood better than a placebo.
This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.
This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.
This study tests an investigational drug called KH607 for adults with major depressive disorder (MDD). It aims to see if the drug can safely and effectively reduce depression symptoms.
This trial tests an investigational medication to see if it can reduce anxiety symptoms in adults with generalized anxiety disorder. Participants will receive the study drug and be monitored for safety and effectiveness.
Hear when a new Major Depressive Disorder (MDD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.